Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) double upgraded to Outperform from Underperform at Macquarie with analyst David Hewitt saying with a "world class" Guyana play, multiple liquefied natural gas developments, the Permian "juggernaut" and growth in the integrated downstream, Exxon is "well positioned for the future, and is not being overly distracted by the energy transition debate." 2. Synchrony (SYF) upgraded to Buy from Neutral at Goldman Sachs with analyst Ryan Nash saying with shares trading at a discount to peers due to credit-related concerns, the current valuation is "compelling." 3. Teva (TEVA) upgraded to Outperform from Market Perform at Raymond James. 4. Elevate Credit (ELVT) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying he views the shares as "simply too inexpensive" at current levels. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."